Securities Class Action Filed Against Lannett Company, CEO, CFO
Last Updated on May 8, 2018
Utesch v. Lannett Company, Inc. et al
Filed: November 16, 2016 ◆§ 2:16-cv-05932-WB
A class action filed against pharmaceutical outfit Lannett Company and its CEO and CFO claims the parties violated federal securities law.
A class action filed against pharmaceutical outfit Lannett Company and its CEO and CFO claims the parties violated federal securities law by making materially false and misleading statements with regard to digoxin, a heart failure and rhythm drug. On July 16, 2014, the defendants received a subpoena from the Connecticut Attorney General investigating whether Lannett, as well as a flock of other big-pharma companies, engaged in any price-fixing or other anti-trust violations in connection with digoxin and other generic medications. Upon the publication of this news, Lannett stock prices sunk roughly 22 percent. When news later came out of a federal investigation into the generic pharmaceutical industry as a whole—which was then followed by the bombshell announcement in November 2016 that the Department of Justice may file criminal charges—Lannett share prices bottomed out even further, prompting the filing of the class action by securities holders.
Hair Relaxer Lawsuits
Women who developed ovarian or uterine cancer after using hair relaxers such as Dark & Lovely and Motions may now have an opportunity to take legal action.
Read more here: Hair Relaxer Cancer Lawsuits
How Do I Join a Class Action Lawsuit?
Did you know there's usually nothing you need to do to join, sign up for, or add your name to new class action lawsuits when they're initially filed?
Read more here: How Do I Join a Class Action Lawsuit?
Stay Current
Sign Up For
Our Newsletter
New cases and investigations, settlement deadlines, and news straight to your inbox.
Before commenting, please review our comment policy.